会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • 4A-aryldecahydroisoquinoline compound and medicinal use of the same
    • 4A-芳基十氢异喹啉化合物及其药用
    • US5776945A
    • 1998-07-07
    • US809226
    • 1997-05-08
    • Hiroshi NagaseYoshifumi ImamuraHiroshi OhnoTakashi Endo
    • Hiroshi NagaseYoshifumi ImamuraHiroshi OhnoTakashi Endo
    • C07D217/16C07D405/12C07D217/04A61K31/46
    • C07D405/12C07D217/16
    • The present invention relates to a 4a-aryldecahydroisoquinoline compound, which is represented by a compound 1, or a pharmacologically acceptable salt thereof. ##STR1## As the results of in vitro and in vivo pharmacological evaluations, it was found that the compounds of the present invention had excellent preventive effects on ischemic death of cerebral neurocytes, suppressive effects on development of cerebral infarction, and strong analgesic and antitussive effects; therefore the compounds of the present invention can be utilized in the medicinal field as a useful cerebral cytoprotective agent, which is aimed at preventing and treating cerebrovascular disorder, ischemic cerebral disorder, cerebral neurocyte disorder, and dementia, an analgesic, and an antitussive.
    • PCT No.PCT / JP96 / 02030 Sec。 371日期:1997年5月8日 102(e)日期1997年5月8日PCT PCT 1996年7月19日PCT公布。 公开号WO97 / 03968 日期:1997年2月6日本发明涉及由化合物1表示的4a-芳基十氢异喹啉化合物或其药理学上可接受的盐。 作为体外和体内药理学评价的结果,发现本发明的化合物对脑神经细胞的缺血性死亡具有优异的预防作用,对脑梗死发展的抑制作用以及强镇痛和镇咳药 效果; 因此,本发明的化合物可用作药用领域,作为有用的脑细胞保护剂,其旨在预防和治疗脑血管障碍,缺血性脑病,脑神经细胞病和痴呆,镇痛药和镇咳药。
    • 5. 发明授权
    • Indole derivatives
    • INDOLE DORIVATIVES
    • US5244904A
    • 1993-09-14
    • US828889
    • 1992-01-29
    • Hiroshi NagaseAkira MizusunaYoshihiro OnodaKoji KawaiShu MatsumotoTakashi Endo
    • Hiroshi NagaseAkira MizusunaYoshihiro OnodaKoji KawaiShu MatsumotoTakashi Endo
    • C07D217/06C07D217/24C07D471/04C07D491/056
    • C07D471/04C07D217/06C07D217/24Y10S514/885
    • This invention is directed to a indole derivative represented by the general formula (1) ##STR1## wherein R.sub.1 stands for alkyl of 1 to 5 carbon atoms, cycloalkylalkyl of 4 to 7 carbon atoms, cycloalkenylalkyl of 5 to 7 carbon atoms, aralkyl of 7 to 14 carbon atoms, trans-alkenyl of 4 to 5 carbon atoms, allyl, furanyl-2-ylalkyl of 1 to 5 carbon atoms, thienyl-2-ylalkyl of 1 to 5 carbon atoms, vinyloxycarbonyl, trichloroethoxycarbonyl, benzyloxycarbonyl, alkanoyl of 1 to 5 carbon atoms, aralkylcarbonyl of 7 to 14 carbon atoms, 2-furoyl, thiophene-2-carbonyl, cycloalkylcarbonyl of 4 to 7 carbon atoms, alkenylcarbonyl of 3 to 8 carbon atoms, or anisoyl, R.sub.2 for a hydrogen atoms, alkyl of 1 to 3 carbon atoms, benzyl, or alkanoyl of 1 to 5 carbon atoms, R.sub.3 for a hydrogen atoms, a fluorine atom, a chlorine atom, a bromine atom, nitro, or alkyl of 1 to 5 carbon atoms, R.sub.4 for a hydrogen atom, alkyl of 1 to 5 carbon atoms, benzyl, or phenyl, and R.sub.5 for a hydrogen atom, hydroxy, or alkanoyloxy of 1 to 5 carbon atoms, providing that said general formula (1) embraces a (+) form, a (-) form, and a (.+-.) form, or a pharmacologically acceptable salt thereof and to an immunorepressing agent having as an active component thereof the indole derivative or the pharmacologically acceptable salt thereof.
    • PCT No.PCT / JP91 / 00759 Sec。 371日期1992年1月29日 102(e)日期1992年1月29日PCT Filed 1991年6月5日PCT公布。 WO91 / 18901 PCT出版物 日本1991年12月12日。本发明涉及由通式(1)表示的吲哚衍生物,其中R1代表1至5个碳原子的烷基,4至7个碳原子的环烷基烷基,环烯基烷基 5至7个碳原子的芳烷基,7至14个碳原子的芳烷基,4至5个碳原子的反式链烯基,1至5个碳原子的烯丙基,呋喃基-2-基烷基,1至5个碳原子的噻吩基-2-基烷基 ,乙氧基羰基,三氯乙氧基羰基,苄氧基羰基,1〜5个碳原子的烷酰基,7〜14个碳原子的芳烷基羰基,2-糠酰基,噻吩-2-羰基,4〜7个碳原子的环烷基羰基,3〜8个碳原子的链烯基羰基, 甲氧基苯甲酰基,R2为氢原子,1〜3个碳原子的烷基,苄基或1〜5个碳原子的烷酰基,R3为氢原子,氟原子,氯原子,溴原子,硝基或烷基 1至5个碳原子,R4代表氢原子,1至5个碳原子的烷基,苄基或苯基,R5代表氢原子,羟基 y)或1至5个碳原子的烷酰氧基,条件是所述通式(1)包含(+)形式,( - )形式和(+/-)形式或其药理学上可接受的盐,以及 作为活性成分的吲哚衍生物或其药理学上可接受的盐的免疫抑制剂。
    • 7. 发明授权
    • Indole derivatives
    • 吲哚衍生物
    • US5539119A
    • 1996-07-23
    • US36521
    • 1993-03-24
    • Hiroshi NagaseAkira MizusunaYoshihiro OnodaKoji KawaiShu MatsumotoTakashi Endo
    • Hiroshi NagaseAkira MizusunaYoshihiro OnodaKoji KawaiShu MatsumotoTakashi Endo
    • C07D217/06C07D217/24C07D471/04C07D491/056C07D217/14
    • C07D471/04C07D217/06C07D217/24Y10S514/885
    • This invention is directed to a indole derivative represented by the general formula (1) ##STR1## wherein R.sub.1 stands for alkyl of 1 to 5 carbon atoms, cycloalkylalkyl of 4 to 7 carbon atoms, cycloalkenylalkyl of 5 to 7 carbon atoms, aralkyl of 7 to 14 carbon atoms, trans-alkenyl of 4 or 5 carbon atoms, allyl, furanyl-2-ylalkyl of 1 to 5 carbon atoms, thienyl-2-ylalkyl of 1 to 5 carbon atoms, vinyloxycarbonyl, trichloroethoxycarbonyl, benzyloxycarbonyl, alkanoyl of 1 to 5 carbon atoms, aralkylcarbonyl of 7 to 14 carbon atoms, 2-furoyl, thiophene-2-carbonyl, cycloalkylcarbonyl of 4 to 7 carbon atoms, alkenylcarbonyl of 3 to 8 carbon atoms, or anisoyl, providing that said general formula (1) embraces a (+) form, a (-) form, and a (.+-.) form, or a pharmacologically acceptable salt thereof and to an immunorepressing agent having as an active component thereof the indole derivative or the pharmacologically acceptable salt thereof.
    • 本发明涉及由通式(1)表示的吲哚衍生物,其中R1表示1至5个碳原子的烷基,4至7个碳原子的环烷基烷基,5至7个碳原子的环烯基烷基, 7至14个碳原子的芳烷基,4或5个碳原子的反式链烯基,1至5个碳原子的烯丙基,呋喃基-2-基烷基,1至5个碳原子的噻吩基-2-基烷基,乙烯氧基羰基,三氯乙氧羰基,苄氧羰基, 具有1至5个碳原子的烷酰基,7至14个碳原子的芳烷基羰基,2-糠酰基,噻吩-2-羰基,4至7个碳原子的环烷基羰基,3至8个碳原子的链烯基羰基或茴香酰基,条件是所述通式 (1)包含(+)形式,( - )形式和(+/-)形式或其药理学上可接受的盐,并且具有作为其活性成分的吲哚衍生物或药理学上可接受的盐的免疫抑制剂 其中。
    • 10. 发明授权
    • Projector
    • 投影机
    • US08823885B2
    • 2014-09-02
    • US13040746
    • 2011-03-04
    • Tomoharu MasudaTakashi Endo
    • Tomoharu MasudaTakashi Endo
    • G02F1/1335G03B21/14H04N9/31G03B33/12
    • G03B21/14G03B21/006G03B21/2053G03B21/206G03B21/2073G03B33/12H04N9/3167
    • A projector includes: an illuminator that outputs illumination light; a light modulator including a liquid crystal panel and a structural birefringent polarization separation element having a polarization separation surface inclined away from a central axis of the illumination light, the light modulator modulating the illumination light from the illuminator; and a projection system that projects the light modulated by the light modulator, wherein the illumination light outputted from the illuminator has an angular distribution in a first direction, which is perpendicular to the central axis of the illumination light, smaller than the angular distribution in a second direction, which is perpendicular to the first direction and the central axis of the illumination light, and the polarization separation surface of the structural birefringent polarization separation element has a structure that is not periodic along the first direction but is periodic along the second direction.
    • 投影仪包括:输出照明光的照明器; 一种光调制器,包括液晶面板和结构双折射偏振分离元件,其具有偏离照明光的中心轴倾斜的偏振分离表面,所述光调制器调制来自照明器的照明光; 以及投影系统,投射由光调制器调制的光,其中从照明器输出的照明光在与照明光的中心轴垂直的第一方向上具有小于角度分布的角度分布 第二方向,其垂直于照明光的第一方向和中心轴,并且结构双折射偏振分离元件的偏振分离表面具有沿着第一方向不是周期性的结构,但沿着第二方向是周期性的。